Clinical Trials Browser

Terminated × NIH × Trastuzumab × Clear all

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT00478140 2019-08-20

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

4 enrolled 6 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Neoplasms

NCT00079326 2014-06-02

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

39 enrolled 8 charts

Breast Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

NCT00006015 2013-05-03

Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

Phase 2 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00126607 2013-02-28

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Phase 2 Terminated

Salivary Gland Neoplasms

NCT00039455 2013-02-01

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Breast Neoplasms, Male